Skip to main content

Table 2 Clinical characteristics according to the first- and second-line treatments

From: Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System

Variables

Total (nā€‰=ā€‰3,247)

First-line treatment

Second-line treatment

Ā Ā 

SUN (1,787, 55.0%)

PAZ (1,460, 45.0%)

p

EVE (2,198, 67.7%)

AXI (773, 23.8%)

CAB (276, 8.5%)

p

Age, mean (SD)

61.27 (10.81)

59.0 (10.05)

64.05 (11.07)

ā€‰<ā€‰0.0001

60.81 (10.77)

62.61 (11.07)

61.16 (10.17)

0.0004

Age group

Ā Ā Ā 

ā€‰<ā€‰0.0001

Ā Ā Ā 

0.0106

ā€ƒā€‰<ā€‰55

849 (26.2)

562 (31.5)

287 (19.7)

Ā 

610 (27.8)

172 (22.3)

67 (24.3)

Ā 

ā€ƒ55ā€“59

529 (16.3)

338 (18.9)

191 (13.1)

Ā 

357 (16.2)

121 (15.7)

51 (18.5)

Ā 

ā€ƒ60ā€“64

623 (19.2)

380 (21.3)

243 (16.6)

Ā 

406 (18.5)

153 (19.8)

64 (23.2)

Ā 

ā€ƒ65ā€“69

459 (14.1)

222 (12.4)

237 (16.2)

Ā 

316 (14.4)

106 (13.7)

37 (13.4)

Ā 

ā€ƒā€‰ā‰„ā€‰70

787 (24.2)

285 (15.9)

502 (34.4)

Ā 

509 (23.1)

221 (28.5)

57 (20.6)

Ā 

Sex (%)

Ā Ā Ā 

ā€‰<ā€‰0.0001

Ā Ā Ā 

0.2816

ā€ƒMale

2,534 (78.0)

1,444 (80.8)

1,090 (74.7)

Ā 

1,700 (77.3)

610 (78.9)

224 (81.2)

Ā 

ā€ƒFemale

713 (22.0)

343 (19.2)

370 (25.3)

Ā 

498 (22.7)

163 (21.1)

52 (18.8)

Ā 

Income level (%)

Ā Ā Ā 

0.3507

Ā Ā Ā 

0.3291

ā€ƒ0%ā€“20% (lowest)

616 (19.0)

326 (18.2)

290 (19.9)

Ā 

402 (18.3)

155 (20.0)

59 (21.3)

Ā 

ā€ƒ20%ā€“40%

468 (14.4)

264 (14.8)

204 (14.0)

Ā 

318 (14.5)

114 (14.8)

36 (13.0)

Ā 

ā€ƒ40%ā€“60%

550 (16.9)

319 (17.9)

231 (15.8)

Ā 

380 (17.3)

121 (15.7)

49 (17.8)

Ā 

ā€ƒ60%ā€“80%

684 (21.1)

381 (21.3)

303 (20.8)

Ā 

451 (20.5)

182 (23.5)

51 (18.5)

Ā 

ā€ƒ80%ā€“100%

929 (28.6)

497 (27.8)

432 (29.5)

Ā 

647 (29.4)

201 (26.0)

81 (29.4)

Ā 

Residence (%)

Ā Ā Ā 

0.1278

Ā Ā Ā 

0.02

ā€ƒMetropolitan

1,538 (47.4)

868 (48.6)

670 (45.9)

Ā 

1,066 (48.5)

333 (43.1)

139 (50.4)

Ā 

ā€ƒOther region

1,709 (52.6)

919 (51.4)

790 (54.1)

Ā 

1,132 (51.5)

440 (56.9)

137 (49.6)

Ā 

CCI (%)

Ā Ā Ā 

0.0071

Ā Ā Ā 

0.7865

ā€ƒ0

1,056 (32.5)

621 (34.8)

435 (29.8)

Ā 

730 (33.2)

237 (30.7)

89 (32.3)

Ā 

ā€ƒ1ā€“2

1,643 (50.6)

884 (49.4)

759 (52.0)

Ā 

1,100 (50.1)

403 (52.1)

140 (50.7)

Ā 

ā€ƒā€‰ā‰„ā€‰3

548 (16.9)

282 (15.8)

266 (18.2)

Ā 

368 (16.7)

133 (17.2)

47 (17.0)

Ā 

Department (%)

Ā Ā Ā Ā Ā Ā Ā 

0.0016

ā€ƒUrology

1,445 (44.5)

941 (52.6)

504 (34.5)

ā€‰<ā€‰0.0001

1,021 (46.5)

323 (41.8)

101 (36.6)

Ā 

ā€ƒInternal

1,753 (54.0)

825 (46.2)

928 (63.6)

Ā 

1,145 (52.0)

434 (56.1)

174 (63.0)

Ā 

ā€ƒOthers

49 (1.5)

21 (1.2)

28 (1.9)

Ā 

32 (1.5)

16 (2.1)

1 (0.4)

Ā 

Time from initial diagnosis to systemic treatment

Ā Ā Ā 

0.8036

Ā Ā Ā 

0.1589

ā€ƒā€‰<ā€‰1Ā year

1,965 (60.5)

1,078 (60.3)

887 (60.7)

Ā 

1,355 (61.6)

448 (58.0)

162 (58.7)

Ā 

ā€ƒā€‰ā‰„ā€‰1Ā year

1,282 (39.5)

709 (39.7)

573 (39.3)

Ā 

843 (38.4)

325 (42.0)

114 (41.3)

Ā 
  1. SUN sunitinib, PAZ pazopanib, EVE everolimus, AXI axitinib, CAB cabozantinib, CCI Charlson Comorbidity Index